Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Clinical Trial ID NCT01037127

Rank	Title	Journal	Year	PubWeight™‹?›
1	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.	Nature	2010	18.69
2	Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.	J Clin Oncol	2012	2.45
3	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	1.96
4	Targeting BRAF for patients with melanoma.	Br J Cancer	2010	1.56
5	The MAPK pathway across different malignancies: a new perspective.	Cancer	2014	1.22
6	Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.	J Carcinog	2010	0.97
7	Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma.	Dermatol Res Pract	2011	0.91
8	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.	Front Oncol	2013	0.89
9	New horizons in melanoma treatment: targeting molecular pathways.	Ochsner J	2010	0.76
10	Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.	Clin Cancer Res	2015	0.76